-transparent.png){kind=logo}
Clinical significance of donor-recipient HLA matching on survival after myeloablative hematopoietic cell transplantation from unrelated donors. 2007
Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA98109, USA. epeters@fhcrc.org
The application of unrelated donor hematopoietic cell transplantation can be expanded with the use of mismatched donors if human leukocyte antigen (HLA) disparity does not lead to increased morbidity and mortality. The rules that govern permissibility of HLA mismatches are not well defined. The International Histocompatibility Working Group in hematopoietic cell transplantation measured the risks associated with locus-specific disparity in 4796 patients transplanted for low, intermediate, or high-risk hematologic diseases. The permissibility of a given HLA mismatch is in part defined by the locus and by disease risk.
Related Publications
E W Petersdorf, and
T Gooley, and
M Malkki, and
M Horowitz, and
May 2006,
Bone marrow transplantation,
E W Petersdorf, and
T Gooley, and
M Malkki, and
M Horowitz, and
January 2000,
Vox sanguinis,
E W Petersdorf, and
T Gooley, and
M Malkki, and
M Horowitz, and
March 2002,
Transplantation proceedings,
E W Petersdorf, and
T Gooley, and
M Malkki, and
M Horowitz, and
August 1995,
Blood,
E W Petersdorf, and
T Gooley, and
M Malkki, and
M Horowitz, and
March 2011,
The Korean journal of hematology,
E W Petersdorf, and
T Gooley, and
M Malkki, and
M Horowitz, and
October 2014,
Blood,
E W Petersdorf, and
T Gooley, and
M Malkki, and
M Horowitz, and
June 2013,
Blood,
E W Petersdorf, and
T Gooley, and
M Malkki, and
M Horowitz, and
November 2007,
International journal of urology : official journal of the Japanese Urological Association,
E W Petersdorf, and
T Gooley, and
M Malkki, and
M Horowitz, and
January 2016,
PloS one,
E W Petersdorf, and
T Gooley, and
M Malkki, and
M Horowitz, and
December 2007,
Blood,
